Table 2.
Details of ALS-CSF
| CSF for iTRAQ study | CSF for validation | |||
|---|---|---|---|---|
| Gender |
Male – 7 (70%) |
Female – 3 (30%) |
Male – 10 (62.5%) |
Female – 6 (37.5%) |
| Age at presentation (Mean ± SD) |
47.40 ± 4.95 (38 – 54) Years |
47.38 ± 5.38 (38 – 54) Years |
||
| Age at onset |
46 ± 5.05 (37 – 53) Years |
46.28 ± 5.36 (37 – 53) Years |
||
| Duration of illness (Mean ± SD) |
15.9 ± 13.4 (4.0 – 48) months |
14.19 ± 10.59 (4.0 – 48) months |
||
| Onset Patter: Bulbar |
1 (10%) |
5 (31.25%) |
||
| Limb onset |
9 (90%) |
11 (68.75%) |
||
| Upper Limbs |
9 |
11 |
||
| Lower Limbs |
6 |
7 |
||
| Speech affected |
80% (Mild – 30%, Moderate – 30%, Severe – 20%) |
87.5% (Mild – 31.25%, Moderate – 31.25%, Severe – 25%) |
||
| Dysphagia |
80% (Mild – 30%, Moderate – 30%, Severe – 20%) |
93.75% (Mild – 31.25%, Moderate – 18.75%, Severe -12.5%) |
||
| Spasticity | 9 cases, with evidence of pyramidal signs in the form of spasticity and exaggerated Deep Tendon Reflexes | 11 cases, with evidence of pyramidal signs in the form of spasticity and exaggerated Deep Tendon Reflexes | ||